2 weeks Ago By ABMN Staff
Turnstone Biologics Corp. ( NASDAQ:TSBX – Get Free Report ) was the recipient of a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 397,100 shares, a decline of 16.
6% from the August 31st total of 476,400 shares. Based on an average daily volume of 266,200 shares, the days-to-cover ratio is currently 1.5 days.
Approximately 2.9% of the company’s shares are sold short. Institutional Inflows and Outflows Several institutional investors have recently added to or reduced their stakes in the stock.
Zimmer Partners LP grew its stake in Turnstone Biologics by 271.4% in the 1st quarter. Zimmer Partners LP now owns 179,026 shares of the company’s stock worth $469,000 after acquiring an additional 130,826 shares in the last quarter.
Kathleen S. Wright Associates Inc. purchased a new stake in shares of Turnstone Biologics in the first quarter valued at approximately $111,000.
Finally, Sei Investments Co. bought a new position in Turnstone Biologics in the second quarter worth approximately $31,000. Hedge funds and other institutional investors own 52.
51% of the company’s stock. Wall Street Analyst Weigh In TSBX has been the topic of several recent research reports. Bank of America decreased their price target on Turnstone Biologics from $12.
00 to $10.00 and set a “buy” rating on the stock in a report on Monday, August 19th. Piper Sandler lowered their target price on shares of Turnstone Biologics from $20.
00 to $3.75 and set an “overweight” rating for the company in a report on Monday, August 19th. Turnstone Biologics Stock Performance TSBX opened at $0.
55 on Friday. The stock’s 50 day moving average price is $1.29 and its 200-day moving average price is $2.
27. Turnstone Biologics has a one year low of $0.54 and a one year high of $5.
75. The stock has a market cap of $12.79 million, a price-to-earnings ratio of -0.
05 and a beta of 2.27. Turnstone Biologics ( NASDAQ:TSBX – Get Free Report ) last announced its quarterly earnings data on Wednesday, August 14th.
The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.
08). As a group, analysts predict that Turnstone Biologics will post -3.9 earnings per share for the current fiscal year.
About Turnstone Biologics ( Get Free Report ) Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.
Featured Stories Receive News & Ratings for Turnstone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turnstone Biologics and related companies with MarketBeat.com's FREE daily email newsletter ..
